<?xml version="1.0" encoding="UTF-8"?>
<p>The high discontinuation rate of trials within 5 months into the pandemic could be due to data from case series and observational studies indicating lack of benefit or even harm with the interventions being tested in RCTs, loss of equipoise, or control of the pandemic resulting in fewer eligible patients for enrolment.</p>
